The Anaplasmosis Treatment Market is projected to reach USD 7,082,85 Million by 2030 at 4.9% CAGR during the forecast period 2022-2030.Anaplasmosis is a bacterial infection that spreads from animals to humans. More rarely, the bacteria that cause anaplasmosis can spread through direct contact with infected animals. The infection can be treated successfully with antibiotics. According to the Centers for Disease Control and Prevention (CDC), the global burden of human anaplasmosis treatment remains high as the organism causes more than 10,000 infections per year worldwide. Usually, anaplasmosis is more common in males than in females and are generally not occurring in infants.
The frequency of reported cases of anaplasmosis is highest among people over 40 years of age. A compromised immune system such as patients undergoing cancer treatments, advanced human immunodeficiency virus infection, prior organ transplants may increase the risk of the severe outcome. Individuals working or spending time in known tick habitats such as the zoo, animal rearing, and farms may be at increased risk for infection.
Although anaplasmosis infections can occur during any time of the year, the majority of cases reported to the CDC have an illness onset during the summer months and peaks in the months of June and July. This period is the season for the proliferation of nymphal black-legged ticks that bite humans and may transmit the pathogen.
Sources: Annual reports, Press release, White paper, and Company presentation
The anaplasmosis treatment market is segmented on the basis of species, diagnosis, application, treatment, and end-users.
On the basis of the species, the Anaplasmosis Treatment Market is segmented into Deer tick (Ixodes scapularis), western black-legged tick (Ixodes pacificus), Anaplasmosis phagocytophilum or A. platys
On the basis of the diagnosis, the Anaplasmosis Treatment Market is segmented into enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody (IFA), and polymerase chain reaction (PCR) tests
On the basis of the application, the Anaplasmosis Treatment Market is segmented into humans, pets, livestock, wildlife, and others
On the basis of the treatment, the Anaplasmosis Treatment Market is segmented into antibiotics, vaccines, and others. The antibiotics can be further classified as doxycycline, tetracyclines, chlortetracycline, oxytetracycline, rolitetracycline, minocycline, and others.
On the basis of the end-user, the Anaplasmosis Treatment Market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, and others.
Some of key the players in the anaplasmosis treatment market are Wyeth Pharmaceuticals (U.S.), Merck Sharp & Dohme (France), Boehringer Ingelheim (France), Bristol-Myers Squibb and Company (U.S.), Glaxosmithkline Inc. (U.S.) Aventis Pharma (Canada), Mylan Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals (Israel), Shire (U.S.), Procter & Gamble, (U.S.), Duramed Pharmaceuticals (U.S.), Takeda Pharmaceuticals (Japan), Ciba Vision (Germany) Novopharm (Canada), and others.
The anaplasmosis treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East, and Africa.
The American anaplasmosis treatment is the largest market across the globe owing to the high investment in various private and government-funded research, and increased spending on pharmaceutical industry. This condition is commonly reported from the upper midwestern and northeastern United States. the black-legged tick (Ixodes scapularis) is responsible for transmission of A. phagocytophilum in the upper Midwest and northeastern U.S. These tick species also transmit the agents of Lyme disease (Borrelia burgdorferi) and babesiosis (Babesia species). Moreover, the human co-infections with these organisms have occasionally been reported. Anaplasmosis treatment is now being controlled in North America due to numerous veterinary control measures such as routine screening and vaccination of domestic livestock.
European market is projected to hold the second largest share of the anaplasmosis treatment market as due to the eradication of these disease from Europe. Although some clinical cases of human granulocytic anaplasmosis have been reported in Europe, mostly from Slovenia, Sweden, and Poland, most cases have occurred in the United States. According to the U.S. National Library of Medicine, the prevalence of Ixodes ricinus ticks in Europe is 3% which is as higher than the United States. The average prevalence rate of A. phagocytophilum infection among humans in Europe was 6.2% in 2010 and is estimated to reach up to 21% by 2020.
The Asia Pacific and the Middle Eastern region are expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the healthcare sector.
The global anaplasmosis treatment market is expected to exhibit a CAGR of 4.9% from 2022 to 2030.
The high frequency of people above 40 being affected with anaplasmosis is the major driver of the global anaplasmosis treatment market.
The Americas can dominate the global anaplasmosis treatment market.
Asia Pacific (APAC) and the Middle East & Africa (MEA) regions can showcase exemplary growth from 2017 to 2023 due to rapid development of the healthcare sector in the regions respectively.
Takeda Pharmaceuticals, Teva Pharmaceuticals, Shire, Ciba Vision, Aventis Pharma, Mylan Pharmaceuticals, Merck Sharp & Dohme, Wyeth Pharmaceuticals, Novopharm, Boehringer Ingelheim, Bristol-Myers Squibb and Company, Glaxosmithkline Inc., Duramed Pharmaceuticals, Pfizer Inc., and Procter & Gamble are notable players of the global anaplasmosis treatment market.